2021
DOI: 10.1002/hon.184_2880
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Introduction: CD19 CAR T cells induce complete remissions in ≥40%of heavily pretreated patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). However, a significant proportion of patients progress early after therapy. Thus, to prospectively identify patients most suitable for currently available commercial CAR T-cell products, we assessed the predictive value of clinical and laboratory parameters for PFS in r/r DLBCL patients treated with Axicabtagene Ciloleucel or Tisagenlecleucel at o… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles